![]() |
市場調查報告書
商品編碼
1383361
2030 年全身麻醉市場預測:按藥物類型、給藥途徑、應用、最終用戶和地區進行的全球分析General Anesthesia Market Forecasts to 2030 - Global Analysis By Type of Drugs (Propofol, Desflurane, Sevoflurane, Thiopental and Other Type of Drugs), Route of Administration (Inhalation and Intravenous), Application, End User and By Geography. |
根據 Stratistics MRC 的數據,2023 年全球全身麻醉市場規模為 60.1 億美元,預計 2030 年將達到 87.4 億美元,預測期內年複合成長率為 6.2%。
全身麻醉是一種在醫療程序或手術期間誘導患者進入意識狀態、鎮痛、肌肉放鬆和失憶的醫療狀況。全身麻醉可以延長手術時間,有利於兒童和老年患者,並有利於嚴重治療和診斷測試。
根據互動式心血管和胸腔外科的數據,到 2022 年 4 月,大約有 227,442 名 70 歲以上的人將接受心血管手術。
外科手術的增加是全身麻醉市場的關鍵促進因素。隨著世界人口的成長和高齡化,對手術介入的需求不斷增加,以解決各種醫療狀況,從常規手術到複雜的救命手術。全身麻醉對於確保患者在這些手術期間的舒適和安全至關重要,因為它會引起受控的意識喪失和鎮痛狀態。此外,新興國家手術技術的進步和醫療基礎設施的擴張也促進了手術數量的增加。對全身麻醉服務和產品的需求不斷成長預計將繼續推動醫療保健行業的市場成長。
麻醉需要專門的設備和藥物,這兩者都可能非常昂貴。麻醉儀器、監視器和藥物的初始資本投資較高,可能會導致醫療機構的財務資源緊張。此外,還存在與維護、藥品供應和符合安全標準的更新相關的持續成本。這種財務負擔可能會限制麻醉服務的獲得,特別是在資源有限的醫療機構中,並可能抑制某些機構提供或擴大麻醉服務,使全身麻醉更加昂貴,並可能限制市場成長。
微創手術(MIS)對於全身麻醉市場來說是一個巨大的機會。這種手術方法包括腹腔鏡檢查和內視鏡等手術,依靠麻醉來確保患者在手術過程中舒適和不動。這種手術因其切口較小、術後疼痛較少、住院時間較短和恢復時間更快等優點而越來越受歡迎。隨著微創手術的需求不斷增加,對適當麻醉服務和產品的需求也增加。在這些微創手術過程中,麻醉在維持病人安全和舒適方面發揮著至關重要的作用,使其成為醫療保健系統不可或缺的一部分,以適應這一不斷成長的趨勢。這一趨勢預計將推動全身麻醉市場的成長。
安全問題是全身麻醉市場的主要威脅。麻醉對於手術期間患者的舒適度至關重要,但也存在固有的風險,包括過敏反應、不利事件和罕見的併發症。與麻醉相關的引人注目的事件可能會削弱公眾的信任並引起患者的擔憂。安全仍然是醫療保健提供者的首要任務,任何感知到的風險都可能阻止患者選擇手術或麻醉。此外,嚴格的安全標準和法規要求可能會增加提供麻醉服務的複雜性和成本。
COVID-19的疫情對全身麻醉市場產生了重大影響。第一波 COVID-19 導致擇期手術延後,以節省資源、優先考慮 COVID-19 患者並降低感染風險。手術量的大幅下降對全身麻醉服務的需求產生了重大影響,影響了麻醉提供者和整個醫療保健行業。此外,供應鏈中斷導致基本麻醉劑和設備的短缺和價格上漲。儘管存在這些挑戰,大流行促使麻醉護理中迅速普及遠端醫療和遠端監控,以盡量減少面對面的接觸。儘管疫情造成了暫時中斷的局面,但醫療保健領域對麻醉服務的需求仍然至關重要,預計市場將在疫情後的情況下恢復和適應。
靜脈注射部分估計佔最大佔有率。全身麻醉市場的靜脈部分是指透過靜脈將麻醉劑直接給藥病人的血液中。此方法可確保麻醉快速起效並可精確控制麻醉效果。靜脈麻醉常用於各種外科手術和醫療干涉,包括全身麻醉的誘導和維持。此外,麻醉師和醫療保健專業人員在整個手術過程中仔細監測和調整藥物給藥,以維持患者的意識、鎮痛和生理穩定性。靜脈麻醉是全身麻醉的基本且多功能的組成部分,有助於提高患者的舒適度、安全性以及手術和醫療干涉的成功。
預計普外科領域在預測期內將出現良好的成長。一般外科包括廣泛的外科手術,不屬於心血管手術或神經外科等專門類別。這些手術通常給藥全身麻醉,以確保患者舒適、肌肉放鬆和失去意識。這使得外科醫生能夠精確地進行各種手術,包括闌尾切除術、疝氣修復和膽囊切除術。此外,一般外科對全身麻醉的需求很高,因為它能夠控制疼痛、固定和受控的手術環境,從而在各種外科手術的成功中發揮著重要作用,並對全身麻醉市場做出了重大貢獻。
在預測期內,亞太地區佔據了最大的市場佔有率。推動亞太地區擴張的因素包括人口快速成長、醫療保健基礎設施的改善以及外科手術機會的增加。該地區的高齡化正在推動外科手術的需求,特別是在中國和印度等國家。此外,先進醫療技術的採用和對病人安全意識的提高也有助於麻醉市場的成長。此外,政府在醫療保健領域的配合措施和外國投資預計將進一步加強亞太地區全身麻醉市場,並成為全球醫療保健格局的關鍵貢獻者。
預計北美在預測期內將實現盈利成長。該地區的特點是醫療基礎設施先進、醫療成本高以及對病人安全的重視。技術進步、嚴格的法規標準以及對患者舒適度和安全性的關注正在推動該市場的持續成長。此外,該地區在麻醉技術、設備和藥品方面擁有重要的研究和創新。該地區的全身麻醉市場對醫療保健仍然至關重要,因為北美醫療保健系統在 COVID-19大流行後重新強調安全性,以適應新的挑戰。
According to Stratistics MRC, the Global General Anaesthesia Market is accounted for $6.01 billion in 2023 and is expected to reach $8.74 billion by 2030 growing at a CAGR of 6.2% during the forecast period. General anaesthesia is a medical state induced in a patient to ensure unconsciousness, analgesia, muscle relaxation, and amnesia during a medical procedure or surgery. It allows for extended surgeries, benefits paediatric and geriatric patients, and facilitates critical care and diagnostic tests.
According to the Interactive cardiovascular and thoracic surgery, in April 2022, it was reported that around 227,442 populations above 70 years undergo cardiovascular procedure.
The increasing number of surgical procedures is a significant driver of the general anaesthesia market. As the global population grows and ages, there is a rising demand for surgical interventions to address various medical conditions, from routine surgeries to complex, life-saving procedures. General anaesthesia is essential in ensuring patient comfort and safety during these surgeries, as it induces a controlled state of unconsciousness and analgesia. Furthermore, advancements in surgical techniques and the expansion of healthcare infrastructure in developing countries contribute to the growing number of surgeries. This increased demand for general anaesthesia services and products is expected to continue driving market growth in the healthcare industry.
Anaesthesia requires specialised equipment and pharmaceuticals, both of which come at a considerable expense. High initial capital investments for anaesthesia machines, monitors, and medication procurement can strain the financial resources of healthcare facilities. Moreover, the ongoing costs of maintenance, drug supplies, and updates to comply with safety standards can be burdensome. This financial burden can limit the accessibility of anaesthesia services, particularly in resource-constrained healthcare settings, and may discourage some facilities from offering or expanding these services, thus restraining the growth of the general anaesthesia market.
Minimally Invasive Surgery (MIS) represents a significant opportunity for the general anaesthesia market. This surgical approach, which includes procedures like laparoscopy and endoscopy, relies on anaesthesia to ensure patient comfort and immobility during surgery. This surgery is gaining popularity due to its benefits, including smaller incisions, reduced postoperative pain, shorter hospital stays, and quicker recovery times. As the demand for minimally invasive surgery procedures continues to rise, the need for appropriate anaesthesia services and products increases. Anaesthesia plays a crucial role in maintaining patient safety and comfort during these minimally invasive surgeries, making it an integral part of the healthcare system's response to this growing trend. This trend is expected to drive the growth of the general anaesthesia market.
Safety concerns represent a significant threat to the general anaesthesia market. Anaesthesia, while crucial for patient comfort during surgery, carries inherent risks, including allergic reactions, adverse events, and rare complications. High-profile cases of anaesthesia-related incidents can erode public trust and raise concerns among patients. Safety remains a paramount focus for healthcare providers, and any perceived risk can deter patients from opting for surgery or anaesthesia. Additionally, stringent safety standards and regulatory requirements can increase the complexity and cost of providing anaesthesia services.
The COVID-19 pandemic has exerted a significant impact on the general anaesthesia market. The initial wave of COVID-19 led to the postponement of elective surgeries to conserve resources, prioritise COVID-19 patients, and reduce infection risk. This substantial reduction in surgical volume significantly affected the demand for general anaesthesia services, impacting both anaesthesia providers and the broader healthcare industry. Additionally, supply chain disruptions led to shortages and increased prices for essential anaesthesia drugs and equipment. Despite these challenges, the pandemic prompted the rapid adoption of telemedicine and remote monitoring in anaesthesia care to minimise in-person contact. While the pandemic had a temporary disruptive effect, the need for anaesthesia services remains essential in healthcare, and the market is expected to recover and adapt in the post-pandemic landscape.
The Intravenous segment is estimated to hold the largest share. The intravenous segment of the general anaesthesia market refers to the administration of anaesthesia drugs directly into the patient's bloodstream via a vein. This method ensures the rapid onset of anaesthesia, allowing for precise control of the anaesthetic effect. IV anaesthesia is commonly used in various surgical procedures and medical interventions, including the induction and maintenance of general anaesthesia. Furthermore, anaesthesiologists and healthcare providers carefully monitor and adjust the drug dosage throughout the procedure to maintain the patient's unconsciousness, analgesia, and physiological stability. IV anaesthesia is a fundamental and versatile component of general anaesthesia, contributing to patient comfort, safety, and the success of surgical and medical interventions.
The General Surgery segment is anticipated to have lucrative growth during the forecast period. General surgery encompasses a wide range of surgical procedures that don't fall under specialised categories like cardiac or neurological surgeries. General anaesthesia is commonly administered in these surgeries to ensure patient comfort, muscle relaxation, and unconsciousness. It enables surgeons to perform various procedures, such as appendectomy, hernia repairs, gallbladder removal, and many more, with precision. Furthermore, the demand for general anaesthesia in general surgery is significant, as it allows for pain control, immobility, and a controlled surgical environment, playing a vital role in the success of diverse surgical interventions and contributing significantly to the general anaesthesia market.
Asia Pacific commanded the largest market share during the extrapolated period. Factors driving its expansion include a burgeoning population, rising healthcare infrastructure, and increasing access to surgical interventions. The region's ageing population has led to a higher demand for surgical procedures, particularly in countries like China and India. Furthermore, the adoption of advanced healthcare technologies and the increasing awareness of patient safety contribute to the growth of the anaesthesia market. Moreover, government initiatives and foreign investments in healthcare are expected to further bolster the Asia-Pacific general anaesthesia market, making it a pivotal contributor to the global healthcare landscape.
North America is expected to witness profitable growth over the projection period. The region is characterised by advanced healthcare infrastructure, high healthcare expenditures, and a strong emphasis on patient safety. Technological advancements, stringent regulatory standards, and a focus on patient comfort and safety drive continuous growth in this market. Additionally, the region is marked by significant research and innovation in anaesthesia techniques, equipment, and pharmaceuticals. The COVID-19 pandemic prompted a renewed emphasis on safety, and North America's healthcare systems have adapted to new challenges, ensuring that the general anaesthesia market in this region remains pivotal in the field of healthcare.
Some of the key players in the General Anesthesia Market include: Baxter International Inc., Pfizer Inc., Fresenius SE & Co. KGaA, Abbott Laboratories, Medtronic plc, AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., GE Healthcare, AstraZeneca plc, Avet Pharmaceuticals Inc, Paion AG, Hikma Pharmaceuticals plc, Aspen Pharmacare Holdings Limited, Claris Lifesciences Limited, Glenmark Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd, Maruishi Pharmaceutical Co. Ltd., Pacira Pharmaceuticals Inc. and Teva Pharmaceutical Industries Limited.
In April 2022, GE Healthcare, a U.S.-based multinational healthcare and medical technology company, received the U.S. Food and Drugs Approval (FDA) pre-market approval (PMA) for its End-tidal (Et) control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System. The device is to have a direct control of the end-tidal concentration that reflects the drug level in the patient's blood along with that low-flow anesthesia has benefits for hospitals and the environment.
In February 2022, Sedana Medical AB has launched Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane) will be approved by the European DCP In addition, in July 2021. the product has been granted national approval in 14 nations. Additional marketing clearance applications were submitted in the same year, and the business expects to gain national approvals in Italy, Poland, Switzerland, and the United Kingdom in 2022.
In January 2022, Akorn Operating Company LLC has agreed to sell seven branded ophthalmic products to Laboratoires Thea SAS (Thea). Thea will be able to add Akorn-branded medicines to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anaesthetic intended for ocular surface anaesthetic during ophthalmologic operations, as a result of the strategic move.